Antibody data
- Antibody Data
- Antigen structure
- References [1]
- Comments [0]
- Validations
- Western blot [3]
- Flow cytometry [1]
- Other assay [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- PA5-17507 - Provider product page
- Provider
- Invitrogen Antibodies
- Product name
- TAK1 Polyclonal Antibody
- Antibody type
- Polyclonal
- Antigen
- Synthetic peptide
- Description
- It is not recommended to aliquot this antibody.
- Reactivity
- Human, Mouse, Rat, Bovine, Chicken/Avian, Xenopus
- Host
- Rabbit
- Isotype
- IgG
- Vial size
- 100 µL
- Storage
- -20°C
Submitted references Therapeutic Benefit of Galectin-1: Beyond Membrane Repair, a Multifaceted Approach to LGMD2B.
Vallecillo-ZĂșniga ML, Poulson PD, Luddington JS, Arnold CJ, Rathgeber M, Kartchner BC, Hayes S, Gill H, Valdoz JC, Spallino JL, Garfield S, Dodson EL, Arthur CM, Stowell SR, Van Ry PM
Cells 2021 Nov 17;10(11)
Cells 2021 Nov 17;10(11)
No comments: Submit comment
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Western blot analysis of MAP3K7 was performed with 10 µg of A549 cells transfected with Transfection Reagent alone (Lane 1), 100nM Non-Targeting control siRNA (Lane 2), or 100nM siRNA against MAP3K7 (Lane 3). Proteins were resolved using a NuPAGE® Novex 4-12% Bis-Tris Gel (Product # NP0322BOX), XCell SureLock™ Electrophoresis System (Product # EI0002), and a protein size ladder. Proteins were wet transferred to a Pierce Nitrocellulose Membrane (Product # 88025) OR Pierce PVDF Membrane (Product # 88518) and blocked with Pierce Starting Block T20 (PBS) Blocking Buffer (Product # 37539) for 1 hour at room temperature. MAP3K7 was detected at ~ 80-82 kDa using MAP3K7 Rabbit polyclonal antibody (Product # PA5-17507) diluted in Pierce Starting Block T20 (PBS) Blocking Buffer 4°C overnight on a rocking platform. Pierce Goat Anti-Rabbit (Product # 31461) HRP-Conjugated Antibodies at a 1:2500 dilution were used and chemiluminescent detection was performed using Pierce Supersignal West Dura Maximum Sensitivity Substrate (Product # 37071). Relative density of the bands normalized to GAPDH (36 kDa). MAP3K7 Antibody (Product # PA5-17507) confirms silencing of MAP3K7 expression.
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Western blot analysis of MAP3K7 was performed with 10 µg of A549 cells transfected with Transfection Reagent alone (Lane 1), 100nM Non-Targeting control siRNA (Lane 2), or 100nM siRNA against MAP3K7 (Lane 3). Proteins were resolved using a NuPAGE® Novex 4-12% Bis-Tris Gel (Product # NP0322BOX), XCell SureLock™ Electrophoresis System (Product # EI0002), and a protein size ladder. Proteins were wet transferred to a Pierce Nitrocellulose Membrane (Product # 88025) OR Pierce PVDF Membrane (Product # 88518) and blocked with Pierce Starting Block T20 (PBS) Blocking Buffer (Product # 37539) for 1 hour at room temperature. MAP3K7 was detected at ~ 80-82 kDa using MAP3K7 Rabbit polyclonal antibody (Product # PA5-17507) diluted in Pierce Starting Block T20 (PBS) Blocking Buffer 4°C overnight on a rocking platform. Pierce Goat Anti-Rabbit (Product # 31461) HRP-Conjugated Antibodies at a 1:2500 dilution were used and chemiluminescent detection was performed using Pierce Supersignal West Dura Maximum Sensitivity Substrate (Product # 37071). Relative density of the bands normalized to GAPDH (36 kDa). MAP3K7 Antibody (Product # PA5-17507) confirms silencing of MAP3K7 expression.
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Western blot analysis of TAK1 in extracts from C6 and COS cells using TAK1 polyclonal antibody (Product # PA5-17507).
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Flow cytometric analysis of TAK1 in HeLa cells using a TAK1 polyclonal antibody (Product # PA5-17507) (blue) compared to a nonspecific negative control antibody (red).
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Figure 2 In vitro treatment with rHsGal-1 modulates inflammatory response through the NF-kappaB pathway. ( A ) Quantification of expression levels of p65 (normalized to beta-tubulin) in 48 h A/J -/- NT or 0.11 muM rHsGal-1 treated myotubes. ( B ) Western blot images showing the p65 expression in NT or 0.11 muM rHsGal-1 48 h A/J -/- treated myotubes. ( C ) Representative images of WT and NT or 0.11 muM rHsGal-1 48 h A/J -/- treated myotubes cultured and immunostained with p65 (green), Phalloidin (red), and DAPI (blue). ( D - H ) Western blot quantification of 48 h NT or 0.11 muM rHsGal-1treated myotubes expressing levels of TAK1 ( D ), NIK ( E ), IKBalpha ( F ), p50 ( G ), and P-p65 ( H ). ( I ) Western blot images of 48 h NT or 0.11 muM rHsGal-1treated myotubes expressing NF-kappaB inflammatory subunits quantified in D-H. n = 3 in each group. A. * p < 0.05 and ** p < 0.01 NT vs. all forms of Gal-1. D-H. * p < 0.05, ** p < 0.01, *** p < 0.001 NT vs. rHsGal-1. Data are represented as SEM.